Bharat Book Bureau provides Market Research Market Report on “Biosimilars Market by Drug Class, Indication, Region – Global Forecast to 2028”UNDER Consumer Goods Market Research Report Category. The report offers a collection of superior market research, market analysis, competitive intelligence and market reports. global The biosimilars market the size is projected to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. Factors such as regulatory approvals, favorable reimbursement policies, increasing demand for cost-effective biosimilars are driving the market growth.
“The monoclonal antibody product segment accounted for the highest growth rate in the biosimilars market, by drug category, during the forecast period” In 2022, the monoclonal antibody product segment accounted for the largest share of the biosimilars market, primarily because of low prices. of biosimilar monoclonal antibodies compared to reference drugs and increased laboratory adoption in the treatment of cancer, autoimmune disorders and osteoporosis. The growth of the fastest growing segment is attributed to the increasing incidence of cancer and chronic diseases globally. Increasing adoption of switchable insulin is likely to have a positive impact on the market. “The oncology segment accounted for the largest share of the indications segment in 2022.” Based on indications, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications. Increasing demand for anti-cancer drugs, growth hormones in various regions is driving the growth of the market. “The Asia Pacific region is likely to grow at a faster rate.” The biosimilars market is segmented into Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. The APAC market is expected to be the fastest growing regional segment during the forecast period owing to the presence of multiple emerging players, less stringent government regulations, and increased collaboration between major and regional players for the development, production and commercialization of biosimilars.
The main interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70%, and Demand Side – 30% • By Definition (Supply Side): Managers – 45%, CXOs & Directors – 30%, Executives- 25% • By Region: Americas North -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of companies profiled in the report:
§Novartis AG (Switzerland) §Pfizer Inc. (USA) §Dr. Reddy’s Laboratories Ltd. (India) §F. Hoffmann-La Roche Ltd (Switzerland) §Eli Lilly & Company (USA) §Amgen Inc. (USA) §Teva Pharmaceutical Industries Ltd. (Israel) §Samsung Biologics (South Korea) §Fresenius SE & Co. KGaA (Germany) § Boehringer Ingelheim International GmbH. (Germany) §STADA Arzneimittel AG (Germany) §Coherus BioSciences (USA) §FUJIFILM Kyova Kirin Biologics Co., Ltd. (Japan) §USV Limited (India), §Amneal Pharmaceuticals LLC. (USA) §Celltrion Healthcare (South Korea) §Biocon (India) §Intas Pharmaceuticals Ltd. (India) §Reliance Life Sciences (India) §AMEGA Biotech (Argentina) §Apotex, Inc. (Canada) §BIOCAD (Russia) § mAbxience (Spain) §Probiomed (Mexico) §Kashiv BioSciences, LLC (USA), §Formycon AG (Germany) §Polpharma Biologics Group (Poland) §Amphastar Pharmaceuticals, Inc. (USA) §Alvotech (Iceland, §UB) Belgium)
Research coverage:
This report provides a detailed overview of the biosimilars market. It aims to estimate the size and future growth potential of the market in various segments such as drug class, indication and region. The report also includes an in-depth competitive analysis of the leading market players, along with their company profiles, recent developments, and key market strategies.
Key benefits of purchasing the report:
The report will assist market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall biosimilars market and its sub-segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make appropriate market entry strategies. This report will enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, opportunities and challenges.
The report provides insights on the following points:
•Analysis of key drivers (Increasing demand for biosimilars, new biosimilar launches, increasing geriatric population and incidence of chronic diseases, shortened regulatory process and switching), constraints (complexities in manufacturing), opportunities (emerging markets, expiration of biologics patents and successful research on new indications), and challenges (excessive competition and regulatory challenges) affecting the growth of the biosimilars market. •Product Development/Innovation: In-depth insights on newly launched products and pipeline analysis of the biosimilars market. •Market development: Comprehensive information about profitable markets – the report analyzes the biosimilars market in different regions. •Market diversification: Comprehensive information on new services, untapped geographies, recent developments and investments in the biosimilars market. •Competition assessment: In-depth assessment of market shares, growth strategies and service offerings of key players such as Novartis AG (Switzerland), Pfizer Inc. (USA), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly & Company (USA), Amgen Inc. (USA) and among others in the biosimilars market.
Browse our full report with Table of Contents:
https://www.bharatbook.com/report/1419444/biosimilars-market-by-drug-class-drug-class-monoclonal-antibodies-adalimumab-infliximab-rituximab-trastuzumab-insulin-erythropoietin-anticoagulants- region-global- the prediction
About Bharat Book Bureau:
Bharat Book is your one stop shop with a comprehensive coverage of 4,00,000 reports and insights that includes the latest Market Research, Market Trends and Analysis, Custom Intelligence Forecasts, Newsletters and Online Databases. Overall, a comprehensive coverage of major industries with a further segmentation of 100+ sub-sectors.
Contact us at:
Bharat Book Bureau Tel: +91 22 27810772 / 27810773 Email: [email protected]
Website: www.bharatbook.com
